| Description | Bendazac (Bendazolic acid) is an anticataract drug. It may act by preventing protein denaturation. |
| In vitro | Bendazac（bendazac L-lysine和sodium）可抑制蛋白质糖化的早期阶段及荧光高级糖化终产品的形成。Bendazac lysine（20 mM）在抑制荧光发展方面证明比相应的sodium salt更有效（67%抑制vs 35%抑制）。对于furosine水平，未发现显著差异；无论是bendazac lysine还是sodium salt，约40%的抑制作用被产生。Bendazac明显可以抑制人类晶状体crystallins的糖化，这可以通过跟踪晶状体蛋白荧光的特定变化有效监测[1]。 |
| Synonyms | AF-983, Bendazolic acid |
| molecular weight | 282.29 |
| Molecular formula | C16H14N2O3 |
| CAS | 20187-55-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 60 mg/mL (212.55 mM) |
| References | 1. Marques C , Ramalho J S , Pereira P , et al. Bendazac decreases in vitro glycation of human lens crystallins. Decrease of in vitro protein glycation by bendazac[J]. Documenta Ophthalmologica, 1995, 90(4):395-404. 2. Lewis B S , Rixon K C , Harding J J . Bendazac prevents cyanate binding to soluble lens proteins and cyanate-induced phase-separation opacities in vitro: a possible mechanism by which bendazac could delay cataract[J]. Experimental Eye Research, 1986, 43(6):0-979. |